There's an easy and emphatic answer.
News & Analysis: Inovio Pharmaceuticals
Lack of detail in a clinical trial report weighed on the shares.
The biotech reported positive results from a preclinical challenge study.
COVID-19 vaccines might not be the moneymakers investors are hoping for.
Shares of the COVID-19 vaccine developer have been on fire in 2020. ,
Investors seem to think a 37% drop this week presents a good opportunity to buy the biotech stock.
Lingering disappointment over results announced on Tuesday and an FDA update are weighing on the stock.
The biotech's "positive" results from an early-stage study weren't positive enough for investors.
One analyst thinks the biotech's shares have come too far too fast.
As COVID-19 cases surge, investors bid up coronavirus vaccine and treatment stocks.
The biotech company announced a contract with the U.S. Department of Defense.